The immune response to breast cancer, and the case for DC immunotherapy

Allan, C. P., Turtle, C. J., Mainwaring, P. N., Pyke, C. and Hart, D. N. J. (2004) The immune response to breast cancer, and the case for DC immunotherapy. Cytotherapy, 6 2: 154-163. doi:10.1080/14653240410005249


Author Allan, C. P.
Turtle, C. J.
Mainwaring, P. N.
Pyke, C.
Hart, D. N. J.
Title The immune response to breast cancer, and the case for DC immunotherapy
Journal name Cytotherapy   Check publisher's open access policy
ISSN 1477-2566
1465-3249
Publication date 2004-04
Sub-type Article (original research)
DOI 10.1080/14653240410005249
Volume 6
Issue 2
Start page 154
End page 163
Total pages 10
Place of publication Abingdon, Oxfordshire
Publisher Taylor & Francis
Language eng
Subject 110323 Surgery
Abstract The long-held belief that breast cancer is a weakly immunogenic tumor and a poor candidate for immunotherapy should be reappraised. There is ample evidence for the existence of an immune response, which is, however, attenuated by multiple inhibitory factors. Many tumor-associated antigens (TAA) have been identified in breast cancer, some of which appear to play a critical role in tumorigenesis and may be attractive targets for immunotherapy. There is evidence for DC recruitment and activation within breast cancers, and the presence of intratumoral activated DCs impacts favorably upon survival. Furthermore, there is a striking paucity of activated DCs within the primary draining or sentinel lymph nodes of breast cancers. Tumor infiltrating lymphocytes (TIL) are often documented, however, their function is impaired by inhibitory cytokines, increased regulatory T lymphocyte activity, tumor cell MHC molecule alterations, and aberrant Fas ligand expression, amongst others. DCs are recognized as one of the critical interfaces between a cancer and the immune system, and have emerged as a promising platform for cancer vaccination via ex vivo immunomodulation. Clinical evaluation of DC vaccination in breast cancer is still relatively limited, although evolving. This article details evidence for the immune response in breast cancer and its many failings, and reviews the clinical trials and significant preclinical data which, taken together, validate the concept of DC vaccination in breast cancer.
Keyword dendritic cell
breast cancer immunotherapy
Q-Index Code C1

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 11 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 13 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 15 Apr 2009, 16:52:33 EST by Maria Campbell on behalf of Faculty Of Health Sciences